These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 28489507)

  • 1. Development and Validation of the PREMM
    Kastrinos F; Uno H; Ukaegbu C; Alvero C; McFarland A; Yurgelun MB; Kulke MH; Schrag D; Meyerhardt JA; Fuchs CS; Mayer RJ; Ng K; Steyerberg EW; Syngal S
    J Clin Oncol; 2017 Jul; 35(19):2165-2172. PubMed ID: 28489507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.
    Goverde A; Spaander MCW; Nieboer D; van den Ouweland AMW; Dinjens WNM; Dubbink HJ; Tops CJ; Ten Broeke SW; Bruno MJ; Hofstra RMW; Steyerberg EW; Wagner A
    Fam Cancer; 2018 Jul; 17(3):361-370. PubMed ID: 28933000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
    Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
    Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
    Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
    J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic mutation risk calculation in Lynch syndrome inheritance: Evaluating the utility of the PREMM
    Aissaoui S; Cartellier C; Seytier T; Giraud S; Calender A
    Bull Cancer; 2017 Mar; 104(3):288-294. PubMed ID: 28038733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline MLH1, MSH2 and MSH6 variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch Syndrome.
    Schneider NB; Pastor T; Paula AE; Achatz MI; Santos ÂRD; Vianna FSL; Rosset C; Pinheiro M; Ashton-Prolla P; Moreira MÂM; Palmero EI;
    Cancer Med; 2018 May; 7(5):2078-2088. PubMed ID: 29575718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer.
    Kastrinos F; Ojha RP; Leenen C; Alvero C; Mercado RC; Balmaña J; Valenzuela I; Balaguer F; Green R; Lindor NM; Thibodeau SN; Newcomb P; Win AK; Jenkins M; Buchanan DD; Bertario L; Sala P; Hampel H; Syngal S; Steyerberg EW;
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26582061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of Lynch syndrome predictive models in quantifying the likelihood of germline mutations in patients with abnormal MLH1 immunoexpression.
    Cabreira V; Pinto C; Pinheiro M; Lopes P; Peixoto A; Santos C; Veiga I; Rocha P; Pinto P; Henrique R; Teixeira MR
    Fam Cancer; 2017 Jan; 16(1):73-81. PubMed ID: 27581132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline variants screening of MLH1, MSH2, MSH6 and PMS2 genes in 64 Algerian Lynch syndrome families: The first nationwide study.
    Boumehdi AL; Cherbal F; Khider F; Oukkal M; Mahfouf H; Zebboudj F; Maaoui M
    Ann Hum Genet; 2022 Nov; 86(6):328-352. PubMed ID: 36073783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
    Yurgelun MB; Kulke MH; Fuchs CS; Allen BA; Uno H; Hornick JL; Ukaegbu CI; Brais LK; McNamara PG; Mayer RJ; Schrag D; Meyerhardt JA; Ng K; Kidd J; Singh N; Hartman AR; Wenstrup RJ; Syngal S
    J Clin Oncol; 2017 Apr; 35(10):1086-1095. PubMed ID: 28135145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
    Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
    Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome.
    Adar T; Rodgers LH; Shannon KM; Yoshida M; Ma T; Mattia A; Lauwers GY; Iafrate AJ; Hartford NM; Oliva E; Chung DC
    Cancer; 2018 Aug; 124(15):3145-3153. PubMed ID: 29750335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
    Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
    Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum of Lynch syndrome-associated germ-line mutations in Russia.
    Yanus GA; Akhapkina TA; Iyevleva AG; Kornilov AV; Suspitsin EN; Kuligina ES; Ivantsov AO; Aleksakhina SN; Sokolova TN; Sokolenko AP; Togo AV; Imyanitov EN
    Eur J Med Genet; 2020 Mar; 63(3):103753. PubMed ID: 31491536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
    Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
    Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2.
    Ten Broeke SW; van Bavel TC; Jansen AML; Gómez-García E; Hes FJ; van Hest LP; Letteboer TGW; Olderode-Berends MJW; Ruano D; Spruijt L; Suerink M; Tops CM; van Eijk R; Morreau H; van Wezel T; Nielsen M
    Gastroenterology; 2018 Sep; 155(3):844-851. PubMed ID: 29758216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PREMM5 distinguishes sporadic from Lynch syndrome-associated MMR-deficient/MSI-high colorectal cancer.
    Sandoval RL; Horiguchi M; Ukaegbu C; Furniss CS; Uno H; Syngal S; Yurgelun MB
    Fam Cancer; 2023 Oct; 22(4):459-465. PubMed ID: 37572151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer.
    Roberts ME; Jackson SA; Susswein LR; Zeinomar N; Ma X; Marshall ML; Stettner AR; Milewski B; Xu Z; Solomon BD; Terry MB; Hruska KS; Klein RT; Chung WK
    Genet Med; 2018 Oct; 20(10):1167-1174. PubMed ID: 29345684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
    Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
    Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.